Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer

Open access
Candido-dos-Reis, Francisco J., Song, Honglin, Goode, Ellen L., Cunningham, Julie M., Fridley, Brooke L., Larson, Melissa C., Alsop, Kathryn, Dicks, Ed, Harrington, Patricia, Ramus, Susan J., de Fazio, Anna, Mitchell, Gillian, Fereday, Sian, Bolton, Kelly L., Gourley, Charlie, Michie, Caroline, Karlan, Beth, Lester, Jenny, Walsh, Christine, Cass, Ilana, Olsson, Håkan, Gore, Martin, Benitez, Javier J., Garcia, Maria J., Andrulis, Irene, Mulligan, Anna Marie, Glendon, Gord, Blanco, Ignacio, Lazaro, Conxi, Whittemore, Alice S., McGuire, Valerie, Sieh, Weiva, Montagna, Marco, Alducci, Elisa, Sadetzki, Siegal, Chetrit, Angela, Kwong, Ava, Kjaer, Susanne K., Jensen, Allan, Høgdall, Estrid, Neuhausen, Susan, Nussbaum, Robert, Daly, Mary, Greene, Mark H., Mai, Phuong L., Loud, Jennifer T., Moysich, Kirsten, Toland, Amanda E., Lambrechts, Diether, Ellis, Steve, Frost, Debra, Brenton, James D., Tischkowitz, Marc, Easton, Douglas F., Antoniou, Antonis, Chenevix-Trench, Georgia, Gayther, Simon A., Bowtell, David, Pharoah, Paul D.P. · 2015 · Clinical Cancer Research

Abstract

Purpose: To analyze the effect of germline mutations in BRCA1 and BRCA2 on mortality in patients with ovarian cancer up to 10 years after diagnosis. Experimental Design: We used unpublished survival time data for 2,242 patients from two case–control studies and extended survival time data for 4,314 patients from previously reported studies. All participants had been screened for deleterious germline mutations in BRCA1 and BRCA2. Survival time was analyzed for the combined data using Cox proportional hazard models with BRCA1 and BRCA2 as time-varying covariates. Competing risks were analyzed using Fine and Gray model. Results: The combined 10-year overall survival rate was 30% [95% confidence interval (CI), 28%–31%] for non-carriers, 25% (95% CI, 22%–28%) for BRCA1 carriers, and 35% (95% CI, 30%–41%) for BRCA2 carriers. The HR for BRCA1 was 0.53 at time zero and increased over time becoming greater than one at 4.8 years. For BRCA2, the HR was 0.42 at time zero and increased over time (predicted to become greater than 1 at 10.5 years). The results were similar when restricted to 3,202 patients with high-grade serous tumors and to ovarian cancer–specific mortality. Conclusions: BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and in BRCA1 carriers is eventually reversed. This may have important implications for therapy of both primary and relapsed disease and for analysis of long-term survival in clinical trials of new agents, particularly those that are effective in BRCA1/2 mutation carriers. Clin Cancer Res; 21(3); 652–7. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2497

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 161

Metadata

Authors
Candido-dos-Reis, F. J., Song, H., Goode, E. L., Cunningham, J. M., Fridley, B. L., Larson, M. C., Alsop, K., Dicks, E., Harrington, P., Ramus, S. J., de Fazio, A., Mitchell, G., Fereday, S., Bolton, K. L., Gourley, C., Michie, C., Karlan, B., Lester, J., Walsh, C., Cass, I., Olsson, H., Gore, M., Benitez, J. J., Garcia, M. J., Andrulis, I., Mulligan, A. M., Glendon, G., Blanco, I., Lazaro, C., Whittemore, A. S., McGuire, V., Sieh, W., Montagna, M., Alducci, E., Sadetzki, S., Chetrit, A., Kwong, A., Kjaer, S. K., Jensen, A., Høgdall, E., Neuhausen, S., Nussbaum, R., Daly, M., Greene, M. H., Mai, P. L., Loud, J. T., Moysich, K., Toland, A. E., Lambrechts, D., Ellis, S., Frost, D., Brenton, J. D., Tischkowitz, M., Easton, D. F., Antoniou, A., Chenevix-Trench, G., Gayther, S. A., Bowtell, D., & Pharoah, P. D. P.
Venue
Clinical Cancer Research
Published
2015-02-01
Volume
21
Issue
3
Pages
652-657
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2111488265
Cited by
161
References
5
FWCI
9.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2497
The paper
Candido-dos-Reis, F. J., Song, H., Goode, E. L., Cunningham, J. M., Fridley, B. L., Larson, M. C., Alsop, K., Dicks, E., Harrington, P., Ramus, S. J., de Fazio, A., Mitchell, G., Fereday, S., Bolton, K. L., Gourley, C., Michie, C., Karlan, B., Lester, J., Walsh, C., . . . Pharoah, P. D. P. (2015). Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2497

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.